

**MEMORANDUM OF UNDERSTANDING
ON PHARMACOPOEIAL COOPERATION
BETWEEN
THE INDIAN PHARMACOPOEIA COMMISSION
MINISTRY OF HEALTH AND FAMILY WELFARE
GOVERNMENT OF THE REPUBLIC OF INDIA
AND
MINISTRY OF HEALTH
GOVERNMENT OF THE REPUBLIC OF TRINIDAD AND TOBAGO**

This Memorandum of Understanding (MoU) is made between the Indian Pharmacopoeia Commission ["IPC"], Ministry of Health and Family Welfare, Government of the Republic of India and the Ministry of Health ["MOH"] Government of the Republic of Trinidad and Tobago [hereinafter referred to individually as "the Party" and jointly as "the Parties"]

RECOGNISING the importance of developing close cooperation and exchanging information in the field of the regulation of medicines in accordance with their respective laws and regulations;

The Parties have reached the following understanding:

1. The MOH undertakes:

- a) following international acceptance of Indian Pharmacopoeia (IP) and the amendment of the Second Schedule to the Food and Drugs Act Chap.30:01 of the laws of Trinidad and Tobago, to accept IP as a book of standards for medicines in Trinidad and Tobago to ensure quality of medicines being manufactured and/or imported in Trinidad and Tobago;

- b) to consider the Certificate of Analysis issued by Indian manufacturers per IP and where accepted, to not test the medicines;
 - c) where appropriate, to obtain IP Reference Substances (IPRS) and Impurity standards from the IPC at a reasonably low cost to be used during the quality control analysis;
 - d) to have better scope for the development of generic medicines which will contribute to the availability of affordable medicines in Trinidad and Tobago;
 - e) to promote an understanding of IP in the regulatory framework, requirements and processes;
 - f) to facilitate the exchange of information and documentation relating to the development of monographs of IP; and
 - g) to explore opportunities for technical cooperation with the IPC in areas of mutual benefit in the development of monographs, future technologies and public health.
2. Each Party will bear its own expenses connected with activities under this MoU.
 3. Each Party is the copyright owner of its respective pharmacopoeia and shall retain all Intellectual Property Rights in the items published. This MoU does not transfer any of the Intellectual Property Rights possessed by the respective Parties. All Intellectual Property Rights developed or created by a Party pursuant to the activities under this MoU shall be owned by that Party.
 4. The MoU is not considered as an international treaty and does not establish any rights and obligations regulated by international law.
 5. The MoU shall enter into force on the date of its signing by both Parties and remain in force until either Party notifies the other Party of its intention to

terminate the MoU by giving notice in writing, through diplomatic channels, at least six (6) months prior to its intention to terminate same.

6. This MoU may be amended by written agreement between the Parties, through diplomatic channels and any difference between the Parties concerning the interpretation and/or application of this MoU shall be settled amicably through mutual consultations through diplomatic channels.

In witness whereof, the undersigned being duly authorized by their respective Governments have signed this Memorandum of Understanding.

Signed on this 4th day of July 2025, at Port of Spain, in two originals in the English language.

**Signed for and on behalf of the
Indian Pharmacopoeia Commission
[IPC], Ministry of Health and Family
Welfare, Government of the
Republic of India**

**Signed for and on behalf of the
Ministry of Health, Government
of the Republic of Trinidad and
Tobago**

Signature: 
Name: Dr. S. Jaishankar
Position: Minister of ~~External~~ Affairs
Date: 4 July 2025

Signature: 
Name: Dr. Lackram Bodo
Position: Minister of Health
Date: 4 July 2025